Laekna Says Obesity Drug Shows Signs of Lean Body Mass, Reduced Fat in Women
MT Newswires Live
Mar 10
Laekna (HKG:2105) completed the phase 1 single ascending dose study of LAE102, which showed signs of increased lean body mass and reduced fat mass in women, according to a Hong Kong bourse filing Tuesday.
After 29 days of treatment, subjects who received the company's drug exhibited a 5.06% increase in mean lean body mass and a 0.12% decrease in mean fat mass from baseline.
The study demonstrated a favorable safety profile, with no serious adverse events.
The firm said the results add to a "growing body of data" supporting the drug's use to treat cardiometabolic diseases. The company is currently planning phase 2 trials of the medicine.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.